Page 1888 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Chapter 129

REFERENCES

1. World Health Organization. International Drug Monitoring: The 15. Duvic M, Lemak NA, Valero V, et al. A randomized trial of min-
Role of the Hospital. Technical Report Series. Geneva: World oxidil in chemotherapy-induced alopecia. J Am Acad Dermatol.
Health Organization; 1966. 1996;35:74.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug 16. Davis M, DeSantis D, Klemm K. A flow sheet for follow-up
reactions in hospitalized patients: a meta-analysis of prospective after chemotherapy extravasation. Oncol Nurs Forum. 1995;
studies. JAMA. 1998;279:1200. 22:979.
3. Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse 17. Bertelli G, Gozza A, Forno GB, et al. Topical dimethylsulfox-
drug events in hospitalized patients: a comparative study of ide for the prevention of soft tissue injury after extravasation
intensive care and general units. Crit Care Med. 1997;25:1289. of vesicant cytotoxic drugs: a prospective clinical study. J Clin
4. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reac- Oncol. 1995;13:2851.
tions: a report from the Boston Collaborative Drug Surveillance 18. Baack BR, Burgdorf WH. Chemotherapy-induced acral ery-
Program on 15438 consecutive inpatients, 1975 to 1982. JAMA. thema. J Am Acad Dermatol. 1991;24:457.
1986;256:3358. 19. Vukelja S, Baker W, Burris H, et al. Pyridoxine therapy for
5. Rawlins M, Thompson J. Mechanisms of adverse drug reac- palmar-plantar erythrodysesthesia associated with Taxotere. J
tions. In: Davies D, ed. Textbook of Adverse Drug Reactions. Natl Cancer Inst. 1993;85:1432.
4th ed. Oxford, England: Oxford University Press; 1991:224. 20. Hwang SW, Hong SK, Kim SH, Seo JK, Lee D, Sung HS. A
6. Hurwitz N. Admissions to hospital due to drugs. Br Med J. Hydroxyurea-induced leg ulcer. Ann Dermatol. 2009;21(1):39-41.
1969;1(643):539. 21. Ben-Amitai D, Hodak E, David M. Cutaneous ulceration: an
7. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. unusual sign of methotrexate toxicity. First report in a patient
2001;137:765. without psoriasis. Ann Pharmacother. 1998;32(6)651-653.
8. Gell PGH, Coombs RRA. Classification of allergic reactions 22. Shear NH, Knowles SR, Shapiro L, Poldre P. Dapsone in preven-
responsible for clinical hypersensitivity and disease. In: Gell PGH, tion of recurrent neutrophilic eccrine hidradenitis. J AM Acad
Coombs RRA, Hachmann PJ, eds. Clinical Aspects of Immunology. Dermatol. 2006;35:819-822.
Oxford, England: Blackwell Scientific Publications; 1975;761. 23. Grassegger A, Fritsch P, Reider N. Delayed-type hypersensitiv-
9. Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United ity and cross-reactivity to heparins and danaparoid: a prospec-
States: an investigation into its epidemiology. Arch Intern Med. tive study. Dermatol Surg. 2001;27:47.
2001;161:15-21. 24. Harenberg J, Hoffmann U, Huhle G, et al. Cutaneous reactions
10. Katta R, Anusuri V. Serum sickness-like reaction to cefurox- to anticoagulants: recognition and management. Am J Clin
ime: a case report and review of literature. J Drugs Dermatol. Dermatol. 2001;2:69.
2007;6(7):747-748. 25. Warkentin TE. Heparin-induced skin lesions. Br J Haematol.
11. Berman B, Villa AM. Is eosinophilia helpful in diagnosing drug 1996;92:494.
eruptions? SkinMED. 2002;1:147. 26. Harenberg J, Huhle G, Wang L, et al. Association of heparin-
12. Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an induced skin lesions, intracutaneous tests, and heparin-induced
indicator of mast-cell activation in systemic anaphylaxis and IgG. Allergy. 1999;54:473.
mastocytosis. N Engl J Med. 1987;316:1622. 27. Gelwix TJ, Beeson MS. Warfarin-induced skin necrosis. Am J
13. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous Emerg Med. 1998;16:541.
reactions to chemotherapy. J Am Acad Dermatol. 1999;40:367. 28. Faraci PA, Deterling RA Jr, Stein AM, et al. Warfarin-induced
14. Rodriguez R, Machiavelli M, Leone B, et al. Minoxidil (Mx) necrosis of the skin. Surg Gynecol Obstet. 1978;146:695.
as a prophylaxis of doxorubicin-induced alopecia. Ann Oncol. 29. Scarff CE, Baker C, Hill P, Foley P. Late-onset warfarin necrosis.
1994;5:769. Australas J Dermatol. 2002;43:202.

Section11-O-Ref.indd 1 12/10/2014 8:08:30 PM